[1]刘璐 张荣智 牛永慧 周平 王迎斌.人诱导多能干细胞用于心血管疾病治疗的研究进展[J].心血管病学进展,2024,(11):1007.[doi:10.16806/j.cnki.issn.1004-3934.2024.11.011]
　LIU Lu,ZHANG Rongzhi,NIU Yonghui,et al.Human Induced Pluripotent Stem Cells in Treatment of Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2024,(11):1007.[doi:10.16806/j.cnki.issn.1004-3934.2024.11.011]
点击复制

人诱导多能干细胞用于心血管疾病治疗的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2024年11期
页码:
1007
栏目:
综述
出版日期:
2024-11-25

文章信息/Info

Title:
Human Induced Pluripotent Stem Cells in Treatment of Cardiovascular Disease
作者:
刘璐1 张荣智1 牛永慧1 周平2 王迎斌1
(1.兰州大学第二医院麻醉科,甘肃 兰州 730000;2 .兰州大学口腔医院颌面外科,甘肃 兰州 730000)
Author(s):
LIU Lu1; ZHANG Rongzhi1; NIU Yonghui1; ZHOU Ping2; WANG Yingbin1
(1.Department of Anesthesiology,The Second Hospital of Lanzhou University,Lanzhou 730000,Gansu,China2. Department of Maxillofacial Surgery,Stomatological Hospital of Lanzhou University,Lanzhou 730000,Gansu,China)
关键词:
心血管疾病;  人诱导多能干细胞; 再生修复; 疾病建模 ; 药物筛选
Keywords:
Cardiovascular disease; Human induced pluripotent stem cells; Regenerative repair; Disease modeling; Drug screening
DOI:
10.16806/j.cnki.issn.1004-3934.2024.11.011
摘要:
现阶段中国心血管疾病高发，传统治疗方式包括药物缓解和介入手术治疗，仅减缓疾病进展而无法逆转已存在的组织损伤，其治疗周期长、患者医从性低。故急需对此类疾病进行更深入的研究，以提出更有效的治疗方案，因此人诱导多能干细胞作为新的突破口为疾病治疗提供了思路。人诱导多功能干细胞不仅可直接替代和间接修复受损的细胞，补偿心脏收缩功能；还能通过构建特定的疾病模型来作为研究个体基因组学、蛋白组学的研究平台，从而深入剖析疾病的机制与进程，实现疾病个体化预测、预防和治疗，达到提高患者心脏泵血功能、延长生存期限的最终目的。现对人诱导多能干细胞用于心血管疾病治疗做一综述。
Abstract:
At present,the incidence of cardiovascular disease is high in China. Traditional treatment methods,including drug relief and interventional surgery,only slow down the progression of the disease but cannot reverse the existing tissue damage,with long treatment cycle and low patient compliance. So there is an urgent?need to conduct in-depth research on these diseases to propose more effective treatment . Therefore,human induced pluripotent stem cells,as a new breakthrough,offer?a new idea for disease treatment. Human induced pluripotent stem cells can not only directly replace and indirectly repair damaged cells,but also compensate for the cardiac systolic function. It can?also build a particular disease model as a research platform for studying individual genomics and proteomics,so as to further analyze the mechanism and process of disease ,achieve individualized disease prediction,prevention and treatment,and achieve the ultimate goal of improving the heart pumping function and extending the survival period of patients. This article briefly reviews the application of human induced pluripotent stem cells in the treatment of cardiovascular diseases

参考文献/References:

[1] Rikhtegar R,Pezeshkian M,Dolati S,et al. Stem cells as therapy for heart disease:iPSCs,ESCs,CSCs,and skeletal myoblasts[J]. Biomed Pharmacother,2019,109:304-313.

[2] Ernst P,Bidwell PA,Dora M,et al. Cardiac calcium regulation in human induced pluripotent stem cell cardiomyocytes:implications for disease modeling and maturation[J]. Front Cell Dev Biol,2022,10:986107.

[3] G?hwiler EKN,Motta SE,Martin M,et al. Human iPSCs and genome editing technologies for precision cardiovascular tissue engineering[J]. Front Cell Dev Biol,2021,9:639699.

[4] Narazaki G,Uosaki H,Teranishi M,et al. Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells[J]. Circulation,2008,118(5):498-506.

[5] Burridge PW,Matsa E,Shukla P,et al. Chemically defined generation of human cardiomyocytes[J]. Nat Methods,2014,11(8):855-860.

[6] Lyra-Leite DM,Gutiérrez-Gutiérrez ?,Wang M,et al. A review of protocols for human iPSC culture,cardiac differentiation,subtype-specification,maturation,and?direct reprogramming[J]. STAR Protoc,2022,3(3):101560.

[7] Stiefbold M,Zhang H,Wan LQ. Engineered platforms for mimicking cardiac development and drug screening[J]. Cell Mol Life Sci,2024,81(1):197.

[8] Blazeski A,Zhu R,Hunter DW,et al. Electrophysiological and contractile function of cardiomyocytes derived from human embryonic stem cells[J]. Prog Biophys Mol Biol,2012,110(2-3):178-195.

[9] Protze SI,Liu J,Nussinovitch U,et al. Sinoatrial node cardiomyocytes derived from human pluripotent cells function as a biological pacemaker[J]. Nat Biotechnol,2017,35(1):56-68.

[10] Liu F,Fang Y,Hou X,et al. Enrichment differentiation of human induced pluripotent stem cells into sinoatrial node-like cells by combined modulation of BMP,FGF,and RA signaling pathways[J]. Stem Cell Res Ther,2020,11(1):284.

[11] Cai Z,Zhu M,Xu L,et al. Directed differentiation of human induced pluripotent stem cells to heart valve cells[J]. Circulation,2024,149(18):1435-1456.

[12] Silva AC,Matthys OB,Joy DA,et al. Co-emergence of cardiac and gut tissues promotes cardiomyocyte maturation within human iPSC-derived organoids[J]. Cell Stem Cell,2021,28(12):2137-2152.e6.

[13] Wickramasinghe NM,Sachs D,Shewale B,et al. PPARdelta activation induces metabolic and contractile maturation of human pluripotent stem cell-derived cardiomyocytes[J]. Cell Stem Cell,2022,29(4):559-576.e7.

[14] Fan X,Cyganek L,Nitschke K,et al. Functional characterization of human induced pluripotent stem cell-derived endothelial cells[J]. Int J Mol Sci,2022,23(15):8507.

[15] Wang K,Lin RZ,Hong X,et al. Robust differentiation of human pluripotent stem cells into endothelial cells via temporal modulation of ETV2 with modified mRNA[J]. Sci Adv,2020,6(30):eaba7606.

[16] Foreman KL,Shusta EV,Palecek SP. Defined differentiation of human pluripotent stem cells to brain microvascular endothelial-like cells for modeling the blood-brain barrier[J]. Methods Mol Biol,2023,2683:113-133.

[17] Romagnuolo R,Masoudpour H,Porta-Sánchez A,et al. Human embryonic stem cell-derived cardiomyocytes regenerate the infarcted pig heart but induce ventricular tachyarrhythmias[J]. Stem Cell Reports,2019,12(5):967-981.

[18] Laflamme MA,Chen KY,Naumova AV,et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts[J]. Nat Biotechnol,2007,25(9):1015-1024.

[19] Gibbs CE,Marchianó S,Zhang K,et al. Graft-host coupling changes can lead to engraftment arrhythmia:a computational study[J]. J Physiol,2023,601(13):2733-2749.

相似文献/References:

[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
　BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(11):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
　REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(11):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[3]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
　YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(11):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[4]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
　ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(11):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[5]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
　QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(11):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[6]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
　JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(11):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[7]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[8]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
　HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(11):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[9]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
　Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(11):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[10]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
　WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(11):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]

更新日期/Last Update: 2024-12-02